AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
MBX Biosciences, Inc. Common Stock
Video analysis: MBX
All videosNo video analysis for this stock yet. Request one from our team.
News: MBX
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
MBX Biosciences to Participate in Upcoming Investor Conferences
CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
CARMEL, Ind. and BURLINGTON, Mass.
Jupiter Topco LLC Acquires Shares of 10,300 MBX Biosciences, Inc. $MBX
Jupiter Topco LLC acquired a new position in shares of MBX Biosciences, Inc. (NASDAQ: MBX) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,300 shares of the company's stock, valued at approximately $568,000. Several other institutional investors and hedge
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
Microbix Reports Results for Q3 Fiscal 2026
Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2026 ended June 30, 2026 ("Q3" and "YTD"). Results for Q3 and YTD continue to demonstrate the results of the Company's continuing work to rebuild revenues back to profitability following two client setbacks in mid-2025, with revenue growth of 17% in Q3 compared to Q3 fiscal 2025.
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High After Analyst Upgrade
MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday after Mizuho raised their price target on the stock from $57.00 to $91.00. Mizuho currently has an outperform rating on the stock. MBX Biosciences traded as high as $66.66 and last traded at $66.46, with a
Similar companies
-
MeiraGTx Holdings plc
MGTX
·
NASDAQ
Compare
-
Replimune Group, Inc.
REPL
·
NASDAQ
Compare
-
ArriVent BioPharma, Inc.
AVBP
·
NASDAQ
Compare
-
Ginkgo Bioworks Holdings, Inc.
DNA
·
New York Stock Exchange
Compare
-
Iovance Biotherapeutics, Inc.
IOVA
·
NASDAQ
Compare
-
MoonLake Immunotherapeutics
MLTX
·
NASDAQ
Compare